203 related articles for article (PubMed ID: 17940978)
1. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice.
Patel A; Zhang Y; Croyle M; Tran K; Gray M; Strong J; Feldmann H; Wilson JM; Kobinger GP
J Infect Dis; 2007 Nov; 196 Suppl 2():S413-20. PubMed ID: 17940978
[TBL] [Abstract][Full Text] [Related]
2. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
[TBL] [Abstract][Full Text] [Related]
3. Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.
Richardson JS; Abou MC; Tran KN; Kumar A; Sahai BM; Kobinger GP
J Infect Dis; 2011 Nov; 204 Suppl 3():S1032-42. PubMed ID: 21987739
[TBL] [Abstract][Full Text] [Related]
4. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.
Croyle MA; Patel A; Tran KN; Gray M; Zhang Y; Strong JE; Feldmann H; Kobinger GP
PLoS One; 2008; 3(10):e3548. PubMed ID: 18958172
[TBL] [Abstract][Full Text] [Related]
5. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.
Jones SM; Stroher U; Fernando L; Qiu X; Alimonti J; Melito P; Bray M; Klenk HD; Feldmann H
J Infect Dis; 2007 Nov; 196 Suppl 2():S404-12. PubMed ID: 17940977
[TBL] [Abstract][Full Text] [Related]
6. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus.
Kobinger GP; Feldmann H; Zhi Y; Schumer G; Gao G; Feldmann F; Jones S; Wilson JM
Virology; 2006 Mar; 346(2):394-401. PubMed ID: 16356525
[TBL] [Abstract][Full Text] [Related]
7. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.
Warfield KL; Swenson DL; Olinger GG; Kalina WV; Aman MJ; Bavari S
J Infect Dis; 2007 Nov; 196 Suppl 2():S430-7. PubMed ID: 17940980
[TBL] [Abstract][Full Text] [Related]
8. Development of a preventive vaccine for Ebola virus infection in primates.
Sullivan NJ; Sanchez A; Rollin PE; Yang ZY; Nabel GJ
Nature; 2000 Nov; 408(6812):605-9. PubMed ID: 11117750
[TBL] [Abstract][Full Text] [Related]
9. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
Feng Y; Li C; Hu P; Wang Q; Zheng X; Zhao Y; Shi Y; Yang S; Yi C; Feng Y; Wu C; Qu L; Xu W; Li Y; Sun C; Gao FG; Xia X; Feng L; Chen L
Emerg Microbes Infect; 2018 Jun; 7(1):101. PubMed ID: 29872043
[TBL] [Abstract][Full Text] [Related]
10. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.
Wilson JA; Bray M; Bakken R; Hart MK
Virology; 2001 Aug; 286(2):384-90. PubMed ID: 11485406
[TBL] [Abstract][Full Text] [Related]
11. Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.
Ko SY; Cheng C; Kong WP; Wang L; Kanekiyo M; Einfeld D; King CR; Gall JG; Nabel GJ
J Virol; 2009 Jan; 83(2):748-56. PubMed ID: 18987146
[TBL] [Abstract][Full Text] [Related]
12. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.
Jones SM; Feldmann H; Ströher U; Geisbert JB; Fernando L; Grolla A; Klenk HD; Sullivan NJ; Volchkov VE; Fritz EA; Daddario KM; Hensley LE; Jahrling PB; Geisbert TW
Nat Med; 2005 Jul; 11(7):786-90. PubMed ID: 15937495
[TBL] [Abstract][Full Text] [Related]
13. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE
J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335
[TBL] [Abstract][Full Text] [Related]
14. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.
Richardson JS; Yao MK; Tran KN; Croyle MA; Strong JE; Feldmann H; Kobinger GP
PLoS One; 2009; 4(4):e5308. PubMed ID: 19390586
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
16. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection.
Warfield KL; Swenson DL; Negley DL; Schmaljohn AL; Aman MJ; Bavari S
Vaccine; 2004 Sep; 22(25-26):3495-502. PubMed ID: 15308377
[TBL] [Abstract][Full Text] [Related]
17. Intranasal immunization with an adenovirus vaccine protects guinea pigs from Ebola virus transmission by infected animals.
Wong G; Richardson JS; Cutts T; Qiu X; Kobinger GP
Antiviral Res; 2015 Apr; 116():17-9. PubMed ID: 25596432
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Friend Virus model for the development of improved adenovirus-vectored anti-retroviral vaccination strategies.
Bayer W; Schimmer S; Hoffmann D; Dittmer U; Wildner O
Vaccine; 2008 Jan; 26(5):716-26. PubMed ID: 18160188
[TBL] [Abstract][Full Text] [Related]
19. A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.
Choi JH; Jonsson-Schmunk K; Qiu X; Shedlock DJ; Strong J; Xu JX; Michie KL; Audet J; Fernando L; Myers MJ; Weiner D; Bajrovic I; Tran LQ; Wong G; Bello A; Kobinger GP; Schafer SC; Croyle MA
Mol Pharm; 2015 Aug; 12(8):2712-31. PubMed ID: 25363619
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of neutralizing antibodies against Ebola virus infection.
Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
